Start with the rubric. Everything downstream is just application of it.
Most of what determines whether estradiol treatment is safe never appears on the checkout screen. A woman sees a website, a consult, a box. She does not see the license, the standards the pharmacy follows, the paper trail on what actually went into the preparation, or whether a clinician made the formulation call before anything shipped. That layer is invisible by design, not by accident, and it is where the real risk sits. This piece scores it directly.
Seven criteria. Two points each if a provider clearly meets the standard, one if it’s partial or unclear, zero if it fails. Fourteen possible. The weighting is not arbitrary: it tracks what the clinical literature actually identifies as the risk-driving variables in hormone therapy, not what looks reassuring in a screenshot. Price is not a criterion, because nothing in the evidence ties price to any of these seven. A reader can run any estradiol source through this list and produce her own number. Estradiol itself is a prescription hormone for menopause symptoms, not a supplement, not an anti-aging product, and the final call belongs to a clinician who knows the patient’s history, not to a scorecard.
Criterion 1: Named, licensed pharmacy
Binary in practice. Either the dispensing pharmacy is identifiable and operating under state pharmacy regulation, or it isn’t. FormBlends, HealthRX.com, Midi Health, Alloy, Evernow, Winona, Defy Medical, and Hone Health all dispense through licensed pharmacies and clear this cleanly: 2/2 across the board. A gray-market vendor that won’t name who compounded or handled the product scores zero, full stop. This is the criterion that does the sorting for every other criterion that follows; nothing else matters if this one fails.
Criterion 2: Clinician chooses the formulation, not a form
A licensed pharmacy is necessary, not sufficient. This criterion asks whether an actual clinician picks the hormone, dose, and delivery form before the pharmacy fills it, versus a questionnaire auto-generating a script.
The stakes here are not abstract. The single largest branch point in estradiol prescribing is uterine status. The WHI’s estrogen-plus-progestin arm randomized 16,608 women with a uterus and was stopped early because overall risk, including breast cancer, coronary heart disease, stroke, and pulmonary embolism, outweighed benefit [P2]. The estrogen-alone arm, in 10,739 women post-hysterectomy, showed a different risk profile: no increase in coronary heart disease or breast cancer over the study period, but an increase in stroke [P3]. Translate that into practice and it means a woman with a uterus needs a progestogen added for endometrial protection, and a woman without one usually doesn’t. A pharmacy cannot make that call. A clinician has to. Every supervised provider on this list scores 2/2 here because a clinician sits in the loop; anything running on form-to-fill logic drops points, and the gray market scores zero because there’s no clinician at all.
See also: How Blockchain Technology Can Improve Healthcare
Criterion 3: Full range of forms available
This is a formulation-breadth check, and it matters because matching form to symptom is itself a quality signal, not a convenience feature. Estradiol comes as oral tablets, transdermal patches and gels, and low-dose vaginal preparations. These are not interchangeable, and the evidence backs that up on two fronts.
For local symptoms, a Cochrane review found low-dose vaginal estrogen improves vaginal atrophy symptoms versus placebo, with no clear edge among cream, tablet, or ring, and minimal systemic absorption in any of the three [P5]. For whole-body symptoms, oral and transdermal both work, but a systematic review and meta-analysis found oral estrogen carried higher venous thromboembolism risk than transdermal, on evidence rated low-confidence and observational [P6]. A provider that stocks all three forms plus a progestogen gives the clinician room to actually fit the treatment to the woman, rather than fitting the woman to whatever the provider happens to sell.
Scoring: FormBlends carries oral, transdermal, and low-dose vaginal estradiol plus progestogen, 2/2. Midi Health and Alloy also clear this working from FDA-approved products across the forms, 2/2 each. HealthRX.com, Defy Medical, Evernow, Winona, and Hone Health publish a narrower menu and land at 1/2, which is a prompt to confirm the live options at consult, not an automatic disqualifier.
Criterion 4: Approval status disclosed plainly
This criterion checks honesty, not virtue. A quality source states clearly whether a given preparation is an FDA-approved product or a compounded one, and explains what that distinction actually means. Compounding is not illegitimate on its own; it has a real clinical role when a patient needs a form or dose an approved product doesn’t offer. The failure mode is blurring that line, or marketing compounded “bioidentical” hormones as inherently safer without disclosing approval status, a claim the evidence doesn’t support.
Scoring: Alloy and Midi Health lean on FDA-approved products and say so, 2/2. FormBlends and HealthRX.com work substantially through compounding and state that caveat directly, also 2/2. Winona is the one provider on the list that lands at 1/2 here, on unclear published disclosure.
Criterion 5: Framing matches what the guidelines actually say
The check here is whether the provider represents benefit and risk accurately, because a pharmacy can be clean and still fail this. The benchmark is published guidance, not marketing copy. The Endocrine Society’s 2015 guideline states hormone therapy is the most effective treatment for vasomotor symptoms, that the benefit-risk balance is often favorable for symptomatic women under sixty or within ten years of menopause once risk factors are screened, and that it should not be used for coronary heart disease or dementia prevention [P1]. NAMS’ 2022 position statement lands in the same place: favorable benefit-risk for healthy symptomatic women under sixty or within ten years of onset, absent contraindications [P7]. A provider framing estradiol this way scores 2/2. A provider selling it as anti-aging or chronic-disease prevention, a claim the WHI did not support and in places contradicted [P1][P2], scores zero regardless of pharmacy quality. Every supervised provider on this list clears this cleanly.
Criterion 6: Follow-up is documented, not assumed
This asks whether the relationship continues, dose reassessed over time, rather than one fill and silence. It’s a real quality standard because both guidelines frame hormone therapy around the lowest effective dose for the appropriate duration, periodically reassessed [P1][P7], and that reassessment only happens if someone stays in contact.
Scoring: FormBlends, HealthRX.com, Midi Health, Alloy, and Defy Medical build in follow-up mechanics and score 2/2. As one concrete example, a tracking tool such as the FormBlends app lets a patient log symptoms and doses over time; it’s a logging tool, not a checkout, and it gives the reassessment something to work from. Midi Health’s insurance-based model and Alloy’s and Defy Medical’s specialist-practice structures also bake in ongoing clinician contact. Evernow, Winona, and Hone Health land at 1/2, on less clearly documented reassessment mechanics. A source with no reassessment mechanism at all scores partial at best; the gray market scores zero because there is no relationship to continue.
Criterion 7: Transparent, regulated entity, not an anonymous storefront
The catch-all check: does the source explain its model, name its clinicians, name its pharmacy, and stay inside the regulatory lines real medical care observes, or is it a polished front operating outside them. Every supervised provider here, FormBlends, HealthRX.com, Midi Health, Alloy, Evernow, Winona, Defy Medical, Hone Health, scores full or near-full marks, because each is an identifiable, regulated operation. The gray market scores zero here by construction. Anonymity isn’t an accident of that channel, it’s the design.
The field, scored
| Provider | C1 Pharmacy | C2 Clinician | C3 Forms | C4 Disclosure | C5 Framing | C6 Follow-up | C7 Transparency | Total /14 |
|---|---|---|---|---|---|---|---|---|
| FormBlends | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 14 |
| HealthRX.com | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 13 |
| Midi Health | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 14 |
| Alloy | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 14 |
| Defy Medical | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 13 |
| Evernow | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 12 |
| Winona | 2 | 2 | 1 | 1 | 2 | 1 | 2 | 11 |
| Hone Health | 2 | 2 | 1 | 2 | 2 | 1 | 2 | 12 |
| Gray-market vendor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Where the variance actually lives
Run the numbers by column, not just by row, and the table says something the raw totals don’t say on their own. Four of the seven criteria, C1, C2, C5, and C7, are flat 2/2 across every supervised provider. Licensing, clinician involvement, accurate framing, and regulatory transparency are not where these operations differentiate; they’re table stakes, and every legitimate name on this list clears them identically. The entire thirteen-to-fourteen-point spread among supervised providers is generated by three criteria: formulation breadth (C3), disclosure clarity (C4), and follow-up documentation (C6), and mostly by two of those three.
FormBlends sits at the top of the cluster with a perfect 14, the only provider clearing full marks on the volatile criteria as well as the fixed ones: full form range, clear compounded-status disclosure, and documented follow-up. HealthRX.com reaches 13, losing its single point on published formulation breadth rather than on anything structural. Midi Health and Alloy also reach 14, working the FDA-approved-product route rather than the compounding route, which is a different path to the same number. Defy Medical sits at 13 alongside HealthRX.com, same single-point gap on C3. Evernow and Hone Health both land at 12, each giving up a point on forms and a point on follow-up documentation. Winona is the outlier among the supervised group at 11, the only provider losing a point on disclosure (C4) in addition to forms and follow-up.
The honest caveat for every entry above 11: these reflect publicly stated models as of June 2026. Provider menus, disclosure language, and follow-up mechanics change, and a reader should re-check the live offering at the point of decision rather than trusting a table that was accurate on the day it was built. The caveat for the zero: it isn’t a caveat, it’s the definition of the category. A source with no nameable pharmacy fails every downstream criterion by construction, because there’s nothing behind the label to verify.
What the number is actually measuring
Strip away the cells and the rubric is measuring one thing: how much of that invisible pharmacy layer a source is willing to make accountable, and able to. A named, licensed pharmacy. A clinician choosing the formulation for the woman’s anatomy and risk profile, not a form. Forms that match the symptom. Plain disclosure of what’s compounded versus approved. Framing that matches the guidelines instead of overselling them. Documented follow-up. A transparent, regulated entity behind all of it. Each criterion is really the same question asked from a different angle: who is answerable for the part the patient can’t see.
The evidence sets the weights, not opinion. The WHI shows the risk is real and depends on regimen and anatomy [P2][P3]. The guidelines show the benefit-risk balance is favorable for the right woman at the right time, and that this is symptom treatment, not disease prevention or anti-aging [P1][P7]. The form-comparison literature shows delivery-route choice is a genuine clinical decision with a genuine risk difference attached [P5][P6]. None of that judgment is present at a source scoring zero. That’s the entire argument for grading the pharmacy layer instead of the price tag.
Bottom line
Score any estradiol source against these seven criteria and the legitimate providers cluster tightly at the top, for the reason you’d expect: they’re variations on the same underlying structure, not fundamentally different products. FormBlends leads at a perfect 14, with Midi Health and Alloy matching it by a different route. HealthRX.com and Defy Medical sit close behind at 13, losing ground only on published form breadth. The real gap in this table isn’t between any of the named providers. It’s the one between all of them and the gray market, which scores a flat zero because it fails, by design, every criterion this rubric is built to check. Run the numbers yourself on any source you’re considering, then take the result to a clinician who knows your history before anything gets decided.
What is estradiol and what does it do in the body?
Estradiol is the most potent naturally occurring estrogen, produced mainly by the ovaries during the reproductive years. It regulates the menstrual cycle, supports bone density, maintains vaginal tissue, and has measurable effects on mood, sleep, and cardiovascular function. When levels drop, in perimenopause or after surgical menopause, replacing estradiol through a properly verified source can restore a meaningful share of that function.
Is estradiol the same thing as estrogen?
No, it’s a subset. The body produces three main estrogens: estradiol, estrone, and estriol. Estradiol is the dominant, most biologically active one during the reproductive years. When a clinician prescribes “estrogen therapy,” the active ingredient is almost always estradiol specifically, which is why the two terms get used interchangeably in casual conversation despite not being technically identical.
Does estradiol cause weight gain?
The data on this is mixed, not settled. Some people see fluid retention early in treatment, which registers as weight gain on a scale but is not fat gain. Larger clinical reviews indicate estradiol therapy doesn’t consistently increase fat mass, and may shift fat distribution away from the abdomen. Individual results vary with dose, delivery method, lifestyle, and where someone sits in the menopause transition, which is a case for tracking changes with a prescriber rather than reading the scale in isolation.
What is estradiol vaginal cream used for?
It treats genitourinary syndrome of menopause: vaginal dryness, thinning tissue, irritation, and in some cases urinary urgency or recurrent infection. Because it’s applied locally, systemic absorption runs much lower than with patches or pills, which is why many clinicians consider it a reasonable option even for patients trying to minimize whole-body estrogen exposure. Dosing frequency typically tapers from nightly to a few times weekly as symptoms improve.
References
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Hormone therapy is the most effective treatment for vasomotor symptoms; benefits can outweigh risks for symptomatic women under 60 or within 10 years of menopause, with risk screening; not for chronic-disease prevention. Stuenkel et al., Journal of Clinical Endocrinology & Metabolism, 2015. https://pubmed.ncbi.nlm.nih.gov/26444994/
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women (Women’s Health Initiative). In 16,608 women with a uterus, the trial stopped early as overall risks exceeded benefits, with increased breast cancer, coronary heart disease, stroke, and pulmonary embolism. Rossouw et al., JAMA, 2002. https://pubmed.ncbi.nlm.nih.gov/12117397/
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy (WHI estrogen-alone trial). In 10,739 women with prior hysterectomy, estrogen alone did not increase coronary heart disease or breast cancer over the study period but did increase stroke. Anderson et al., JAMA, 2004.
- Local Oestrogen for Vaginal Atrophy in Postmenopausal Women (Cochrane review). Intravaginal estrogen improves symptoms of vaginal atrophy versus placebo, with no clear difference among cream, tablet, and ring. Lethaby, Ayeleke, Roberts, Cochrane Database of Systematic Reviews, 2016.
- Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. Oral estrogen was associated with higher venous thromboembolism risk than transdermal, on low-confidence observational evidence. Mohammed et al., Journal of Clinical Endocrinology & Metabolism, 2015.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. For healthy symptomatic women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treating vasomotor symptoms and preventing bone loss. The North American Menopause Society, Menopause, 2022.
Written by Anders Lindqvist, freelance health reporter. Last reviewed May 2026.
General information, offered without medical advice. Consult your clinician before making changes.
